Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintor Pharmaceutical Limited has announced the approval of its tyrosinase inhibitor, KT-939, by the International Cosmetic Ingredient Nomenclature Committee, paving the way for its application in the booming whitening and freckle-removing cosmetics market. The compound has demonstrated superior efficacy and safety compared to existing alternatives, positioning it as a promising ingredient for high-end cosmetic products. This development could enhance Kintor’s competitive edge and market share in the cosmetics industry.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.